Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Running

FeROS Prodrugs oF antiparasitic RedOx-active compoundS

Coordinator
Centre National De La Recherche Scientifique CNRS, France
Runs
1 March 2026 to 28 February 2030
Status
Running
EU funding
€3.0m
Total cost
€3.0m
Partners
6 organisations in 4 countries
Type
European Innovation Council
Grant agreement
101259120

What the project is doing

In the project's own words, from its summary on CORDIS.

With 600,000 deaths per year, malaria remains the most devastating parasitic disease for humans. The efficiency of artemisinin-based combination therapy, the spearhead of malarial treatment, is now threatened by the development of drug resistant parasites displaying enhanced transmission potential to mosquitoes. Chagas disease, leishmaniasis and schistosomiasis are neglected tropical parasitic diseases that are considered as the greatest missed opportunities atop the priorities for WHO.

The FeROS project is based on the discovery of promising non-quinonoid chemotypes as precursors of 3-benzylmenadiones, with specific antiparasitic profiles depending on the substitution pattern. FeROS will follow convergent and complementary objectives: (i) to develop innovative and specific antiparasitic prodrugs in specific series of optimized drug-candidates to reach total cures in infected animal models for four human parasitic diseases, (ii) to extend the concept to animal health, (iii) to draw structure-activity relationships in in vitro and in vivo parasite assays, (iv) to build innovative chemical tools to visualize the release of active principles under ROS fluxes, in living parasites upon drug treatment, (v) to decipher the molecular and cellular mechanisms that underlie prodrug antiparasitic activities and selectivity.

FeROS is built on the multidisciplinary expertise of 7 laboratories from France, Belgium, Switzerland and USA. In an interdisciplinary approach, we will combine a large set of expertise, ranging from medicinal chemistry, physico(bio)chemistry, proteomics to parasite genetics and molecular and cellular parasitology to optimize the antiparasitic non-quinonoid prodrugs of 3-benzylmenadiones, to unravel their mode of action and take them to early clinical studies.

Topics

Who is involved

OrganisationCityCountryRole
Centre National De La Recherche Scientifique CNRSParisFranceCoordinator
Universiteit AntwerpenAntwerpenBelgiumParticipant
Invenesis SARLSt-BlaiseSwitzerlandParticipant
Schweizerisches Tropen Und Public Health InstitutAllschwilSwitzerlandParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceThird party
University of Nebraska Medical CenterOmahaUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI